New pill shows promise for diabetes control in Real-World study

NCT ID NCT04862923

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in everyday UK clinics. Researchers tracked blood sugar levels and weight changes over 8-10 months in 336 participants. The goal was to see if the pill helps lower blood sugar and improve health in real-world conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral semaglutide (Rybelsus)
What this could lead to: If successful, this study could confirm that oral semaglutide effectively lowers blood sugar and helps with weight loss in real-world type 2 diabetes patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It also only lasted 8-10 months, so long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Master Centre for United Kingdom

Gatwick, West Sussex, RH6 0PA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.